Revospirone

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 1,1-dioxo-2-[3-(4-pyrimidin-2-ylpiperazin-1-yl)propyl]-1,2-benzothiazol-3-one

| image = Revospirone.svg

| width = 220

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 95847-87-3

| ATC_prefix = none

| ATC_suffix =

| PubChem = 72024

| ChemSpiderID = 65018

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 6X8764TW2J

| C = 18 | H = 21 | N = 5 | O = 3 | S = 1

}}

Revospirone (Bay Vq 7813) is an azapirone drug which was patented as a veterinary tranquilizer but was never marketed.{{cite book | vauthors = Macdonald F | title = Dictionary of Pharmacological Agents | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA1744 | access-date = 13 May 2012 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 1744}} It acts as a selective 5-HT_1A receptor partial agonist.{{cite journal |vauthors=Löscher W, Witte U, Fredow G, Traber J, Glaser T | title = The behavioural responses to 8-OH-DPAT, ipsapirone and the novel 5-HT1A receptor agonist Bay Vq 7813 in the pig | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 342 | issue = 3 | pages = 271–7 |date=September 1990 | pmid = 2149168 | doi = 10.1007/bf00169437| s2cid = 24769939 }} Similarly to other azapirones such as buspirone, revospirone produces 1-(2-pyrimidinyl)piperazine (1-PP) as an active metabolite. As a result, it also acts as an α₂-adrenergic receptor antagonist to an extent.